Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Lung: Immunotherapy-Based Combinations in Metastatic NSCLC
2023-504038-23-00Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoint: Objective response rate. Started Jun 2024; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504038-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504038-23-00.